This inventor holds 70 USPTO granted patents, plus 2 CIPO patents, primarily in Fatty Acid Therapeutics (CPC class 4244). Top assignees: Scotia Holdings Plc., Efamol Holdings Plc, Efamol Limited. Active years: 1987-2006.
Inventors with similar research interests:
Location History:
- Guildford, Surrey, GB (1993)
- Lythe Hill Park, GB (1993)
- Haslemere, GB (1988 - 1995)
- Surrey, GB (1987 - 1999)
- Guildford, Surrey, GU1 1BA, GB (2000)
- Guildford, GB (1988 - 2003)
- Scotland, GB (2003)
- Stirling, GB (1999 - 2006)
Company Filing History:
31 out of 34Â 
17 out of 20Â 
12 out of 33Â 
Years Active: 1987-2006
Areas of Expertise:
Title: **David F Horrobin: Innovator in Pain Treatment and Nutritional Therapy**
Introduction
David F Horrobin is a prominent inventor based in Guildford, GB, renowned for his significant contributions to the fields of pain treatment and nutritional therapy. With an impressive portfolio of 70 patents, Horrobin has made a notable impact on medical and dietary innovations.
Latest Patents
Among Horrobin's latest patents, two stand out prominently. The first is titled "Treatment of pain," which outlines a method of alleviating pain by the co-administration of an antidepressant alongside one or more precursors or inducers of neurotransmitters. The method specifically highlights amino acids such as L-phenylalanine, L-tyrosine, L-tryptophan, and L-DOPA, demonstrating a novel approach to pain management.
The second patent focuses on "Therapeutic and dietary compositions containing essential fatty acids and bioactive disulfides." This invention details compositions that include gamma-linolenic acid (GLA) and/or other essential fatty acids (EFAs) combined with thioctic acid or related compounds. These compositions are crafted to enhance therapy or nutrition, particularly aiming to improve cell membrane EFA concentration and alleviate complications arising from diabetes, such as impaired nerve function and blood flow.
Career Highlights
Throughout his career, David F Horrobin has worked with notable companies, including Scotia Holdings Plc and Efamol Holdings Plc. His endeavors in these organizations underscore his dedication to advancing health-related innovations and therapies.
Collaborations
Horrobin's ability to collaborate with fellow innovators has been instrumental in his success. Among his notable coworkers are Mehar S Manku and Philip Knowles, who have contributed to various projects aimed at enhancing therapeutic outcomes and nutritional benefits.
Conclusion
In conclusion, David F Horrobin stands as a noteworthy figure in the realms of pain treatment and nutritional therapy. His extensive patent portfolio reflects his commitment to innovation and improvement in healthcare, particularly through his recent advancements in therapeutic compositions. Horrobin's contributions continue to inspire ongoing research and development in these vital fields.